RSV antagonist | RSV inhibitor | RSV agonist

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S8588	ACSS2 inhibitor	ACSS2 inhibitor is the most potent and specific inhibitor of acetate-dependent acetyl-CoA synthetase 2 (ACSS2). ACSS2 inhibitor also inhibits the respiratory syncytial virus (RSV).	Nat Commun, 2024, 15(1):3200 Research (Wash D C), 2024, 7:0400 Cell Commun Signal, 2024, 22(1):187
S0470	RSV604	RSV604 (A-60444), a novel benzodiazepine, is an inhibitor of respiratory syncytial virus (RSV) with EC50 of 0.86 μM. RSV604 has significant potential for the effective treatment of RSV disease. Phase 2.	Biomed Environ Sci, 2023, 36(2):135-145
E1398	Rilematovir	Rilematovir (JNJ-678, JNJ-53718678) is an antiviral agent that inhibits respiratory syncytial virus (RSV) with EC50 of 1.2 nM in HBECs. Rilematovir is also a fusion protein inhibitor.
A2364	Palivizumab (Anti-RSV-F)	Palivizumab (Anti-RSV-F) is a humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. MW : 145.5 kD.
S8588	ACSS2 inhibitor	ACSS2 inhibitor is the most potent and specific inhibitor of acetate-dependent acetyl-CoA synthetase 2 (ACSS2). ACSS2 inhibitor also inhibits the respiratory syncytial virus (RSV).	Nat Commun, 2024, 15(1):3200 Research (Wash D C), 2024, 7:0400 Cell Commun Signal, 2024, 22(1):187
S0470	RSV604	RSV604 (A-60444), a novel benzodiazepine, is an inhibitor of respiratory syncytial virus (RSV) with EC50 of 0.86 μM. RSV604 has significant potential for the effective treatment of RSV disease. Phase 2.	Biomed Environ Sci, 2023, 36(2):135-145
E1398	Rilematovir	Rilematovir (JNJ-678, JNJ-53718678) is an antiviral agent that inhibits respiratory syncytial virus (RSV) with EC50 of 1.2 nM in HBECs. Rilematovir is also a fusion protein inhibitor.
A2364	Palivizumab (Anti-RSV-F)	Palivizumab (Anti-RSV-F) is a humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. MW : 145.5 kD.

RSV

RSV製品

RSV阻害剤の選択性比較